Search results

  1. V.R.T.

    Circulating levels of GDF15 in patients with myalgic encephalomyelitis/chronic fatigue syndrome, 2019, Melvin, Lacerda, Nacul et al

    Having come across this study, I find it surprising (but perhaps not that surprising given the state of the field) that there has been no replication attempt. How do we feel about this study six years on? Do we still think it has potential as a biomarker/drug target? I think the idea that...
  2. V.R.T.

    Should we initiate development of a new, short questionnaire to identify PEM (to aid diagnosis)?

    Someone should tell that to a lot of the doctors I've seen in the last nine years.
  3. V.R.T.

    scRNA-seq reveals persistent aberrant differentiation of nasal epithelium driven by TNFα and TGFβ in post-COVID syndrome, 2025, Reddy et al.

    Are there drugs on the market that target this pathway? Is this model positing that the abberant signalling is occuring exclusively in nasal tissues or elsewhere too? And do we think this type of issue could cause the symptoms of ME/CFS?
  4. V.R.T.

    News from PrecisionLife Ltd.

    I was thinking along these lines earlier before you posted this! Great minds! The daratumumab example is good because it could be many different things - 2 different diseases, sub optimal drug effectiveness linked to NK cell levels, nk cell levels as a marker for something else etc. My main...
  5. V.R.T.

    News from PrecisionLife Ltd.

    I'm also a bit skeptical about the claims of hetrogeniaty - I'm not saying there is only one illness under ME/CFS, there may well be more, but the whole 'there's 15 different subsets and all the treatments the community use actually work but only in subsets' thing always makes me a bit iffy.
  6. V.R.T.

    News from PrecisionLife Ltd.

    See I'm more excited about what other people can do with this new paper than what precisionlife themselves are planning. Although that could pay off big time if thats how pharma get interested. But really I want to see how these data complement DecodeME and Zhang and what the smart people here...
  7. V.R.T.

    Serum GDF15 as a supportive biomarker in female fibromyalgia patients based on a prospective case-control study, 2025, Yigit et al

    https://s4me.info/tags/gdf15/ Previous mentions of GDF15. Proposed as a biomarker in LC last year. No difference in ME/CFS in a recent Fluge and Mella paper (Hoel et al)
  8. V.R.T.

    Serum GDF15 as a supportive biomarker in female fibromyalgia patients based on a prospective case-control study, 2025, Yigit et al

    So this means that 47% of people got a false negative result? If this study is bona fide what implications would that have? Is that expected/normal?
  9. V.R.T.

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    So I may be misremembering but the Sanofi OX40L monoclonal was claimed by the company to have a t cell calming/soothing effect, and JE and others have theorised T Cells may be central to the mechinism of MECFS. So I was going from that and the connections I saw iirc. But i didnt realise it was...
  10. V.R.T.

    News from PrecisionLife Ltd.

    Oh yes that's the most important part and I forgot to mention it :banghead:
  11. V.R.T.

    News from PrecisionLife Ltd.

    https://www.healthrising.org/blog/2025/10/27/precisionlife-chronic-fatigue-long-covid/ Healthrising article, a write up of a long interview with Steve Gardner. Some interesting information. Apparently they have identified TLR4 as of interest and so are interested in LDN. I find the obsession...
  12. V.R.T.

    If a cure for ME/CFS was found tomorrow, would our GPs reach out to tell us?

    If a drug were discovered to be 100% effective and a permanent cure for all pwME (life is never that simple I know), we would still have a fight with the BPS people on our hands, because pwME misdiagnosed with serious untreatable depression or FND or whatever who have no idea ME/CFS exists would...
  13. V.R.T.

    How quickly could an effective drug treatment for ME/CFS be rolled out once approved?

    I think three things would be on our side in this situation. A) An effective treatment would legitimise our struggle in the eyes of doctors and the public, and the NHS will want to counter the seriously negative publicity as how they've treated us seeps into the wider public conciousness. B)...
  14. V.R.T.

    CSF immune cell alterations in women with neuropsychiatric Long COVID, 2025, Orlinick et al.

    Inspired by @ryanc97's post in the bone marrow thread, I wanted to ask about what kind of evidence we would need to proceed with a t cell soothing or depleting drug trial in ME/CFS, and how specific said treatments would need to be. I know you have mentioned Campath in the past, and daratumumab...
  15. V.R.T.

    scRNA-seq reveals persistent aberrant differentiation of nasal epithelium driven by TNFα and TGFβ in post-COVID syndrome, 2025, Reddy et al.

    Two papers mentioning TGF beta today! We haven't talked about the idea that abberant cell signalling could be occurring in the nose. Perhaps these findings support the case for more tissue biopsy studies generally? Personal note- Ever since I got covid at the tail end of my ME/CFS...
  16. V.R.T.

    Blood diagnostic biomarkers for neurologic manifestations of long COVID, 2025, Padhye et al.

    Only 48 patients, and we see these kind of papers all the time. But TGF beta coming up here, which as we discussed yesterday has been seen increased in ME/CFS before. As well as c5a and IFN-a. Interferons obviously being discussed a lot lately, especially by @jnmaciuch and @Jonathan Edwards...
  17. V.R.T.

    Optimising and beta-testing a user-centred, accessible, self-management rehabilitation smartphone app reCOVer…, 2025, McCready, Newton+

    The PACE trial method of rigorous study design! If you have a result you don't like, duke the stats so it goes away!
  18. V.R.T.

    Optimising and beta-testing a user-centred, accessible, self-management rehabilitation smartphone app reCOVer…, 2025, McCready, Newton+

    It has just struck me that what the psychobehavioural school have built, in these apps and the BACME style services and all of it, are burecratic patient crippling machines. That is not what they call them of course, but if we take the view that the purpose of a thing is what it does, that is...
Back
Top Bottom